QC
MRTX

Quent Capital’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Quent Capital’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-57
Closed -$3.35K – 1380
2023
Q4 		$3.35K Buy
57
+18
+46% +$1.01K ﹤0.01% 1140
2023
Q3 		$1.7K Sell
39
-974
-96% -$34.8K ﹤0.01% 1199
2023
Q2 		$36.6K Buy
1,013
+992
+4,724% +$40.9K 0.01% 669
2023
Q1 		$781 Hold
21
– – ﹤0.01% 1251
2022
Q4 		$952 Buy
21
+13
+163% +$841 ﹤0.01% 1231
2022
Q3 		$1K Hold
8
– – ﹤0.01% 1205
2022
Q2 		$1K Hold
8
– – ﹤0.01% 1152
2022
Q1 		$1K Buy
+8
New +$818 ﹤0.01% 1246

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Quent Capital's MRTX Position: Q1 2024 in Review

Quent Capital sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 57 shares — an estimated $3.35K sold.

Quent Capital first reported a position in MRTX in Q1 2022 and held it in 8 quarters. The position peaked at $36.6K in Q2 2023. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • Quent Capital reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Quent Capital sold 57 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $3.35K.
  • Quent Capital first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2022 and held it in 8 quarters.
  • Quent Capital's Mirati Therapeutics, Inc. Common Stock position peaked at $36.6K in Q2 2023.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Quent Capital's 13F filing for Q1 2024, filed 2 May 2024.